Apellis Pharmaceuticals Inc. has identified C3 convertase inhibitors reported to be useful for the treatment of cancer, obesity, infections, neurological disorders, autoimmune and inflammatory disorders, age-related macular degeneration and chronic obstructive pulmonary disease (COPD), among others.
Recombination Therapeutics LLC and Thomas Jefferson University have synthesized DNA polymerase θ (POLQ) inhibitors reported to be useful for the treatment of cancer.
Researchers from University of Washington presented the discovery of novel bumped kinase inhibitor (BKI) derived compound (BKIDC), BKIDC-1553, being developed for the treatment of prostate cancer.
Researchers from Shanghai Jiao Tong University presented data from a study that aimed to assess the role of long intergenic non-protein coding RNA 1605 (LINC01605) in the progression of pancreatic ductal adenocarcinoma (PDAC).
Guangdong Newopp Biopharmaceuticals Co. Ltd. has identified macrocyclic derivatives acting as ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.
Jiangsu Mingsheng Jutai Biotechnology Co. Ltd. has patented β-catenin (CTNNB1)/BCL9 interaction inhibitors reported to be useful for the treatment of cancer and fibrosis.
Researchers from Northeast Normal University in Changchun demonstrated that compound AW-01178 reversed the abnormal regulation of E-cadherin by inhibiting the class I HDAC enzyme.
RSS
